← brief for 2026-09-01 · Slowing decline

COMBINING SGLT2 INHIBITORS AND FINERENONE IN CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME: A CLINICAL UPDATE

Paper No results yet Peer reviewed

Key takeaways

This is a clinical update on using two kidney protection drugs together: SGLT2 inhibitors, which make the kidneys pass extra sugar out in the urine, and finerenone, which blocks a hormone that drives kidney scarring. Each drug on its own is already known to slow kidney decline. The update discusses giving both to people who have heart, kidney and metabolic problems at the same time. It is a summary of work already published, not a new trial, so it reports no new results.

Who did this work

Przemysław Krukowski · Zuzanna Gąsior · Maria Grabowska · Michał Stermach · Michał Maciejowski · Mateusz Zdaniewicz · Zuzanna Lecyk · Agata Leszek · Kacper Ćwiek · Adrianna Przedborska

Source

Paper · OpenAlex, CKD works · 2026-08-31
https://doi.org/10.35630/2026/16/iss.4.10